Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197


Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.

Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J, Wassink M, Boon L, Ruers TJ, Figdor CG, Schoenberger SP, Adema GJ, Janssen EM.

Cancer Res. 2011 Oct 15;71(20):6428-37. doi: 10.1158/0008-5472.CAN-11-2154. Epub 2011 Jul 25.


Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

Nierkens S, den Brok MH, Roelofsen T, Wagenaars JA, Figdor CG, Ruers TJ, Adema GJ.

PLoS One. 2009 Dec 18;4(12):e8368. doi: 10.1371/journal.pone.0008368.


Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice.

Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P.

J Clin Invest. 2008 Mar;118(3):1165-75. doi: 10.1172/JCI33583.


CpG-A stimulates Hsp72 secretion from plasmacytoid dendritic cells, facilitating cross-presentation.

Tanaka T, Kajiwara T, Kutomi G, Kurotaki T, Saito K, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T, Hirata K, Okamoto Y, Sato N, Tamura Y.

Immunol Lett. 2015 Sep;167(1):34-40. doi: 10.1016/j.imlet.2015.06.014. Epub 2015 Jun 30.


Conventional but not plasmacytoid dendritic cells foster the systemic virus-induced type I IFN response needed for efficient CD8 T cell priming.

Hervas-Stubbs S, Riezu-Boj JI, Mancheño U, Rueda P, Lopez L, Alignani D, Rodríguez-García E, Thieblemont N, Leclerc C.

J Immunol. 2014 Aug 1;193(3):1151-61. doi: 10.4049/jimmunol.1301440. Epub 2014 Jun 27.


Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.

Ali OA, Verbeke C, Johnson C, Sands RW, Lewin SA, White D, Doherty E, Dranoff G, Mooney DJ.

Cancer Res. 2014 Mar 15;74(6):1670-81. doi: 10.1158/0008-5472.CAN-13-0777. Epub 2014 Jan 30.


Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.

Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M.

J Clin Invest. 2012 Feb;122(2):575-85. doi: 10.1172/JCI61034. Epub 2012 Jan 17.


Facilitated antigen uptake and timed exposure to TLR ligands dictate the antigen-presenting potential of plasmacytoid DCs.

Kool M, Geurtsvankessel C, Muskens F, Madeira FB, van Nimwegen M, Kuipers H, Thielemans K, Hoogsteden HC, Hammad H, Lambrecht BN.

J Leukoc Biol. 2011 Dec;90(6):1177-90. doi: 10.1189/jlb.0610342. Epub 2011 Sep 20.


Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.

Simmons DP, Canaday DH, Liu Y, Li Q, Huang A, Boom WH, Harding CV.

J Immunol. 2010 Aug 15;185(4):2405-15. doi: 10.4049/jimmunol.0904005. Epub 2010 Jul 21.


Suppressive oligodeoxynucleotides induced tolerogenic plasmacytoid dendritic cells and ameliorated the experimental autoimmune neuritis.

Wang YZ, Lv H, Hao YL, Zhang HQ, Li L, Cai GM, Hu M, Jia CX, Feng XG, Kong QX.

Immunol Lett. 2015 Jul;166(1):13-8. doi: 10.1016/j.imlet.2015.04.007. Epub 2015 May 5.


TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection.

Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, Wang Y, Venzon D, Epstein SL, Segal DM.

J Immunol. 2011 Feb 15;186(4):2422-9. doi: 10.4049/jimmunol.1002845. Epub 2011 Jan 17.


Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.

Masuda Y, Nawa D, Nakayama Y, Konishi M, Nanba H.

J Leukoc Biol. 2015 Dec;98(6):1015-25. doi: 10.1189/jlb.1A0814-415RR. Epub 2015 Aug 21.


CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8α+ dendritic cells [corrected].

de Brito C, Tomkowiak M, Ghittoni R, Caux C, Leverrier Y, Marvel J.

J Immunol. 2011 Feb 1;186(3):1503-11. doi: 10.4049/jimmunol.1001022. Epub 2010 Dec 27. Erratum in: J Immunol. 2011 Jun 15;186(12):7272.


Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation.

Guiducci C, Ott G, Chan JH, Damon E, Calacsan C, Matray T, Lee KD, Coffman RL, Barrat FJ.

J Exp Med. 2006 Aug 7;203(8):1999-2008. Epub 2006 Jul 24.


Analysis of DC Functions Using CD205-DTR Knock-In Mice.

Fukaya T, Takagi H, Uto T, Arimura K, Sato K.

Methods Mol Biol. 2016;1423:291-308. doi: 10.1007/978-1-4939-3606-9_21.


Type I interferon dependence of plasmacytoid dendritic cell activation and migration.

Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, Trinchieri G.

J Exp Med. 2005 Apr 4;201(7):1157-67. Epub 2005 Mar 28.


Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.

Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS.

Blood. 2010 Mar 11;115(10):1949-57. doi: 10.1182/blood-2009-08-238543. Epub 2010 Jan 11.


STAT2 Is Required for TLR-Induced Murine Dendritic Cell Activation and Cross-Presentation.

Xu J, Lee MH, Chakhtoura M, Green BL, Kotredes KP, Chain RW, Sriram U, Gamero AM, Gallucci S.

J Immunol. 2016 Jul 1;197(1):326-36. doi: 10.4049/jimmunol.1500152. Epub 2016 May 27.


Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.

Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G.

Eur J Immunol. 2002 Nov;32(11):3235-45.

Supplemental Content

Support Center